Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]
There is some good budgetary news as it now appears that the CDMRP (the Department of Defense) programs, including the Peer Reviewed Prostate Cancer Program, are funded at the omnibus level (last year’s level). The bill has not yet passed and is still vulnerable to changes. As of today, this is how the budget looks: [...]
Researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth. Their research was presented at the recent Annual Meeting of the American Association for Cancer Research (AACR) which I had the good fortune to attend. As we know the common treatment for localized [...]
I just heard the shocking, but not really surprising news that only 28 members of the House of Representatives have signed onto the appropriations request letter this year for the funding of the Department of Defense Congressionally Directed Medical Research Program for Prostate Cancer. […]
